ResearcherFirst Affiliated Hospital of Fujian Medical UniversityNo recent work listed
Yan-song Zheng
Matched on ORCID iD 0000-0001-9621-5134; OpenAlex author ID A5071769149. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 2
2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper
Papers 2
- Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer. Last author DOI 10.1080/15384047.2023.2258566↗
- NUDT21 knockdown inhibits proliferation and promotes apoptosis of pancreatic ductal adenocarcinoma through EIF2 signaling. Co-author DOI 10.1016/j.yexcr.2020.112182↗
Closest collaborators
The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mingliu Chen · 2 shared papers, 2020–2023 · strength 0.34
- Paper Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer. DOI 10.1080/15384047.2023.2258566↗
- Paper NUDT21 knockdown inhibits proliferation and promotes apoptosis of pancreatic ductal adenocarcinoma through EIF2 signali… DOI 10.1016/j.yexcr.2020.112182↗
- Yingchun Liu · 2 shared papers, 2020–2023 · strength 0.34
- Paper Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer. DOI 10.1080/15384047.2023.2258566↗
- Paper NUDT21 knockdown inhibits proliferation and promotes apoptosis of pancreatic ductal adenocarcinoma through EIF2 signali… DOI 10.1016/j.yexcr.2020.112182↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.